TRDA

Entrada TherapeuticsF

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$11.00

+65.7% vs current

Most likely

Base case

45%

Probability

Target price

$7.50

+13.0% vs current

B-

Bear case

30%

Probability

Target price

$4.00

-39.8% vs current

AI sentiment snapshot

Latest data as of 2026-05-08

AI commentary

Sentiment has turned decisively cautious after the May 7, 2026 readout: company materials framed Cohort 1 as positive, but trusted coverage tied the >50% stock drop to disappointment around dystrophin magnitude and pediatric exposure versus expectations. With no reliable post-print analyst revision set available in the checked evidence and coverage still thin, TRDA now looks more like a monitoring situation than a clean rebound thesis until mid-2026 and year-end follow-up data clarify whether the PK explanation truly rescues efficacy expectations.

RankAlpha Sentiment Codex - 2026-05-08

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-05-31catalystPost-readout revision cycle may keep shares volatile after the May 7 resetHigh impact

Near-term trading is likely to stay headline-driven after TRDA lost more than half its value on May 7, 2026 as analysts and investors focused on lower-than-expected dystrophin and drug-exposure data despite favorable safety and early functional signals; the next few sessions matter for whether the selloff stabilizes or continues.

2026-07-15eventELEVATE-45-201 Cohort 1 data remain the next clean platform proof pointHigh impact

Entrada said ENTR-601-45 Cohort 1 dosing is underway and the company remains on track to report Cohort 1 data in mid-2026, giving investors a second Duchenne exon-skipping readout after the mixed initial ENTR-601-44 reaction [#8-K-2026-05-07].

2026-12-31eventENTR-601-44 open-label plus Cohort 2 data are now critical to repairing the thesisHigh impact

Following lower-than-expected pediatric plasma exposure in Cohort 1, management said updated PK modeling supports higher exposure at 12 mg/kg and expects ELEVATE-44-201 open-label and Cohort 2 data by year-end 2026; stronger exposure, dystrophin and function data are now the main recovery catalyst [#8-K-2026-05-07].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-05-08 • Updated nightlySource: Internal modelMethodology